StockDuty ← Dashboard Sep 30, 2026 10:19 AM ET
SignalFDA/Bio

ABBVIE'S ABBV-295 DELIVERS UP TO 9.8% WEIGHT LOSS IN PHASE 1 - SEEKINGALPHA

AbbVie's ABBV-295 Phase 1 obesity drug shows up to 9.8% weight loss.

What changed
AbbVie's ABBV-295 Phase 1 obesity drug shows up to 9.8% weight loss.
Why it matters
AbbVie's ABBV-295 Phase 1 obesity drug shows up to 9.8% weight loss. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →